Scientists Create “Self-Exercising” Muscle Implants That Contract Under the Skin to Replace Gym Workouts

Biologists from the Chinese Academy of Sciences have developed living muscle grafts (myografts) capable of continuous, autonomous contraction after subcutaneous implantation. According to a study published in Nature Aging, the bioengineered tissue reproduces the physiological effects of physical exercise, increasing muscle mass, strengthening bones, and slowing systemic aging without actual workouts.

The researchers grew mature muscle tissue using an organism’s own cells: after implantation under the skin, it successfully integrates with blood vessels and begins spontaneous mechanical contractions.

Myokine Secretion and Systemic Anti-Aging Effects

The main therapeutic effect of the technology relies on the endocrine function of muscles. During any contraction, muscle fibers release myokines into the bloodstream—regulatory peptides that stimulate metabolism and help restore internal organ function.

Experiments on aged and obese mice confirmed the therapeutic effect of these continuous impulses:

• Halting age-related muscle fiber degradation (sarcopenia) and boosting physical endurance;
• Improving lipid metabolism and clearing fat deposits from the liver;
• Increasing bone mineral density and suppressing markers of neurodegeneration in brain tissue.

A Living Biofactory of Therapeutics for Bedridden Patients

According to South China Morning Post, project lead Ng Shi-Chung views the development as a rehabilitation therapy for severely ill, paralyzed patients, and elderly people for whom physical stress on joints and the cardiovascular system is contraindicated.

Researchers were able to genetically program the myografts to continuously synthesize beneficial therapeutic proteins—specifically growth hormone and parathyroid hormone, which promote fracture healing and accelerate tissue regeneration.

Human Clinical Trials

Scientists caution against viewing the innovation as a commercial way to build muscle without effort: widespread clinical application of the technology is still years of safety testing away.

According to data from the Chinese Clinical Trial Registry (ChiCTR), official human trials will start September 1, 2026, and run through February 2028. The pilot group will consist of six patients, in whom doctors will assess autologous cell engraftment, capillary network formation, and changes in bone density.